Gallwitz B, Schmidt W E, Conlon J M, Creutzfeldt W
Division of Gastroenterology and Endocrinology, Georg August University, Göttingen, Federal Republic of Germany.
J Mol Endocrinol. 1990 Aug;5(1):33-9. doi: 10.1677/jme.0.0050033.
Glucagon-like peptide-1(7-36)amide (GLP-1(7-36)amide) is a potent stimulator of insulin secretion. Receptors for this hormone have been found on different insulinoma-derived cell lines, e.g. the RINm5F cell line which is derived from a radiation-induced rat insulinoma. To characterize the part of the GLP-1(7-36)amide molecule that is responsible for binding to its receptor on RINm5F cells, binding studies with synthetic C-terminal (GLP-1(21-36)amide) and synthetic N-terminal (GLP-1(7-25] GLP-1 fragments were carried out. GLP-1(21-36)amide showed dose-dependent binding to the GLP-1(7-36)amide receptor but was approximately 1500 times less potent in inhibiting binding of 125I-labelled GLP-1(7-36)amide than the intact hormone. GLP-1(7-25) at concentrations up to 10 mumol/l did not inhibit binding of label. Neither fragment changed intracellular cyclic AMP concentrations, in contrast to GLP-1(7-36)amide which increased intracellular cyclic AMP. GLP-1(21-36)amide, however, acted as a weak partial antagonist of GLP-1(7-36)amide with respect to GLP-1(7-36)amide-dependent stimulation of cyclic AMP production.
胰高血糖素样肽-1(7-36)酰胺(GLP-1(7-36)酰胺)是胰岛素分泌的强效刺激剂。已在不同的胰岛素瘤衍生细胞系上发现了这种激素的受体,例如源自辐射诱导的大鼠胰岛素瘤的RINm5F细胞系。为了表征GLP-1(7-36)酰胺分子中负责与RINm5F细胞上其受体结合的部分,进行了与合成C末端(GLP-1(21-36)酰胺)和合成N末端(GLP-1(7-25))GLP-1片段的结合研究。GLP-1(21-36)酰胺显示出与GLP-1(7-36)酰胺受体的剂量依赖性结合,但在抑制125I标记的GLP-1(7-36)酰胺的结合方面,其效力比完整激素低约1500倍。浓度高达10μmol/L的GLP-1(7-25)不抑制标记物的结合。与增加细胞内环状AMP的GLP-1(7-36)酰胺相反,这两个片段均未改变细胞内环状AMP浓度。然而,就GLP-1(7-36)酰胺依赖性刺激环状AMP产生而言,GLP-1(21-36)酰胺作为GLP-1(7-36)酰胺的弱部分拮抗剂起作用。